Objective: The aim of the study was to investigate the impact of treatment-related clearance of hepatitis C virus (HCV) on cognitive function. Methods: A prospective study was conducted in 19 HCV-monoinfected and 15 HIV/HCV-coinfected individuals undergoing pegylated interferon α-2a and ribavirin therapy between April 2003 and August 2005. Neuropsychological, mood, and health-related quality of life (HRQOL) effects were assessed using computer-based battery, Trail Making Tests, Depression Anxiety Stress Scales and the Short Form-36 health survey. Results: Pretreatment cognitive function, mood status, and HRQOL were similar between the HCV patient groups. Sustained virological response (SVR) rates were similar between HCV-monoinfected (68%) and HIV/ HCV-coinfected (73%) groups. SVR was associated with significant improvements in some measures of cognitive function, independent of HRQOL improvement. Conclusions: Our findings provide evidence to support cognitive effects of HCV independent of mood status and HRQOL profiles. © 2007 British HIV Association.
CITATION STYLE
Thein, H. H., Maruff, P., Krahn, M. D., Kaldor, J. M., Koorey, D. J., Brew, B. J., & Dore, G. J. (2007). Improved cognitive function as a consequence of hepatitis C virus treatment. HIV Medicine, 8(8), 520–528. https://doi.org/10.1111/j.1468-1293.2007.00505.x
Mendeley helps you to discover research relevant for your work.